Showing 6811-6820 of 7701 results for "".
- Experts Call for Improved Identification of "High Burden" Rosacea Patients in Everyday Practicehttps://practicaldermatology.com/news/experts-call-for-improved-identification-of-high-burden-rosacea-patients-in-everyday-practice/2457605/Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report called Rosacea: Beyond the visible, assists healthcare professionals in identifying the common char
- New Study Examines Safety and Efficacy of Higher Dose Botox Cosmetichttps://practicaldermatology.com/news/new-study-examines-safety-and-efficacy-of-higher-dose-botox-cosmetic/2457609/Allergan plc conducted a clinical trial to evaluate the duration of effect and safety of Botox Cosmetic 40, 60, and 80 unit doses versus Botox Cosmetic 20 unit dose in patients with moderate to severe glabellar lines. The primary efficacy endpoint was met and was statistically significant f
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit
- New Laser Handpiece Clears Multicolor Tattoos in Fewer Treatmentshttps://practicaldermatology.com/news/new-laser-handpiece-clears-multicolor-tattoos-in-fewer-treatments/2457613/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a new study in Lasers in Surgery and Medicine (LSM). Researchers led by American Soc
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Mind the Gap: Disparity Between Urban and Rural Derms Widenshttps://practicaldermatology.com/news/mind-the-gap-disparity-between-urban-and-rural-derms-widens/2457618/The gap between dermatologists in urban and rural areas is widening across the United States, according to a new study of county-level data from 1995 to 2013 in JAMA Dermatology. Specifically, derm
- Bee Venom May Help Treat Eczemahttps://practicaldermatology.com/news/bee-venom-may-help-treat-eczema/2457619/Bee venom and its major component, melittin, may be effective treatments for atopic dermatitis, according to a British Journal of Pharmacology study. Through studies conducted in mice and in human cells, inv
- Novel Epigenetic Mechanism May Cause Drug Resistance in Melanomahttps://practicaldermatology.com/news/novel-epigenetic-mechanism-may-cause-drug-resistance-in-melanoma/2457634/New research sheds light on epigenetic reason for drug resistance in melanoma, and identifies potential therapies that may prevent such resistance, according to a paper in Nature Communications. Mount Sinai researchers identified a novel e
- Lupin Launches Generic Clobetasol Cream in the UShttps://practicaldermatology.com/news/lupin-launches-generic-clobetasol-cream-in-the-us/2457637/Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier.
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the